Episode

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

Podcast

The Long Run with Luke Timmerman

Published

Dec 15, 2025

Duration seconds

4054

Processing state

not_requested

Canonical source

https://soundcloud.com/longrunpodcast/ep191-emily-conley-on-small-molecules-to-correct-a-rare-kidney-disease

Audio

https://feeds.soundcloud.com/stream/2230123736-longrunpodcast-ep191-emily-conley-on-small-molecules-to-correct-a-rare-kidney-disease.mp3

JSON

/v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep191-emily-conley-on-small-molecules-to-correct-a-rare-kidney-disease

Markdown

/podcast/the-long-run-with-luke-timmerman-1124799/ep191-emily-conley-on-small-molecules-to-correct-a-rare-kidney-disease.md

Actions

• POST https://stenobird.com/v1/public/podcasts/the-long-run-with-luke-timmerman-1124799/episodes/ep191-emily-conley-on-small-molecules-to-correct-a-rare-kidney-disease/transcription-requests
  Idempotently request low-priority transcript generation for this episode.
• GET https://stenobird.com/podcast/the-long-run-with-luke-timmerman-1124799/ep191-emily-conley-on-small-molecules-to-correct-a-rare-kidney-disease.md
  Read the agent-friendly Markdown representation of this episode resource.

Summary

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).